Single-cell and spatial transcriptomics reveal that THBS1 induces radiation resistance in TNBC through the interaction between myCAF and TOPBP1⁺ tumor cells.
- 1Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Hospital, No. 1, Huanhu West Road, Tiyuan North Road, Hexi District, Tianjin, 300060, China.
- 2Tianjin Medical University, Tianjin, 300060, China.
- 3Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Hospital, No. 1, Huanhu West Road, Tiyuan North Road, Hexi District, Tianjin, 300060, China. [email protected].
Abstract
Background
Radiation resistance remains a clinical challenge in the treatment of triple-negative breast cancer (TNBC) and its mechanisms are not yet fully understood.Methods
We integrated single-cell RNA sequencing, spatial transcriptomics, and prognostic data to perform analyses such as intercellular communication, pseudo-temporal trajectories, and GSEA and validated the results using experiments including qPCR, single-cell sequencing and flow cytometry.Results
This study identified a unique subpopulation of epithelial cells, designated TOPBP1⁺ E.T. cells, which retain normal epithelial transcriptional profiles and are associated with poor patient prognosis. myCAF communicates with this cell cluster via the THBS1 signaling pathway, activating the NOTCH signaling pathway to promote resistance to radiotherapy.Conclusions
THBS1 plays a pivotal role in mediating radioresistance in triple-negative breast cancer, positioning it as a promising therapeutic target.
Related
- Single-cell spatial transcriptomics identifies SERPINE1 as a vascular endothelial mediator of cisplatin resistance in head and neck squamous cell carcinoma.
- The Role of Spatial Transcriptomics in Exploring the Tumor Microenvironment in Neuroblastoma
- Spatial transcriptomics reveals interferon pathway enrichment in early relapsing serous carcinoma
- Integrated scRNA‐Seq and Spatial Transcriptomics Reveal CHPF and GPC1 as Markers of Cancer‐Associated Fibroblast–Dominant Domains in Colorectal Cancer
- High-resolution spatial transcriptomics reveals fibroblast and neuroimmune microenvironments in endometriosis lesions
BibTeX
@article{liu2026singlecell,
title = {{Single-cell and spatial transcriptomics reveal that THBS1 induces radiation resistance in TNBC through the interaction between myCAF and TOPBP1⁺ tumor cells.}},
author = {Fuzhong Liu and Xing Xu and Wenhao Tong and Yang Xie and Yecheng Ma and Lingling Yang and Xun Jin},
journal = {Journal of translational medicine},
year = {2026},
month = jul,
doi = {10.1186/s12967-026-08614-z},
url = {https://europepmc.org/article/MED/42902364},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Single-cell and spatial transcriptomics reveal that THBS1 induces radiation resistance in TNBC through the interaction between myCAF and TOPBP1⁺ tumor cells.
AU - Fuzhong Liu
AU - Xing Xu
AU - Wenhao Tong
AU - Yang Xie
AU - Yecheng Ma
AU - Lingling Yang
AU - Xun Jin
PY - 2026
DA - 2026/07/01
JO - Journal of translational medicine
DO - 10.1186/s12967-026-08614-z
UR - https://europepmc.org/article/MED/42902364
AB - Background Radiation resistance remains a clinical challenge in the treatment of triple-negative breast cancer (TNBC) and its mechanisms are not yet fully understood.Methods We integrated single-cell RNA sequencing, spatial transcriptomics, and prognostic data to perform analyses such as intercellular communication, pseudo-temporal trajectories, and GSEA and validated the results using experiments including qPCR, single-cell sequencing and flow cytometry.Results This study identified a unique subpopulation of epithelial cells, designated TOPBP1⁺ E.T. cells, which retain normal epithelial transcriptional profiles and are associated with poor patient prognosis. myCAF communicates with this cell cluster via the THBS1 signaling pathway, activating the NOTCH signaling pathway to promote resistance to radiotherapy.Conclusions THBS1 plays a pivotal role in mediating radioresistance in triple-negative breast cancer, positioning it as a promising therapeutic target.
SN - 1479-5876
ER -